Investor News Archives - Page 2 of 16

Apr 4 2024

Halberd’s Patented Drug, LDN+, the Subject of a Limited Clinical Trial under an Innovative Four-company Cooperative Research and Development (CRADA) Contract.

By Admin|2024-04-04T17:47:08-04:00April 4th, 2024|Featured, Investor News, Medical, News, Press Releases|0 Comments

Jackson Center, PA, April 4, 2024 – Halberd Corporation’s (OTC-PINK: "HALB”) Patented LDN+ Drug hits an enormous milestone as it enters a significant Safety Trial Protocol under a CRADA contract for Military Active Duty and Veterans. Halberd Corporation's patented drug, LDN+, a combination of low-dose Naltrexone and Cyclobenzaprine, is a central part of a just ...

Feb 8 2024

Halberd and Mississippi State University to Commence Stage II Advanced TBI Nasal Spray Testing

By Admin|2024-02-08T08:07:03-05:00February 8th, 2024|Featured, Investor News, News, Press Releases|0 Comments

Jackson Center, PA February 8, 2024 – Halberd Corporation’s (OTC-PINK: "HALB”) Traumatic Brain Injury (TBI) mitigating nasal spray testing protocols at Mississippi State University (MSU) were approved by the Institutional Animal Care and Use Committee. Dr. Russell Carr, the Primary Investigator, initiated preparations for this extension of the successful Phase #1 pilot test program, completed ...

Feb 7 2024

Halberd’s Top Executives Join Forces with Athena GTX CEO Mark Darrah Unveiling 2024 Powerful Partnership Outlook on “The Street Reports Podcast”

By Admin|2024-02-07T17:33:32-05:00February 7th, 2024|Investor News, News, Press Releases|0 Comments

JACKSON CENTER, PA February 6, 2024 -- Halberd Corporation’s (OTC: HALB) and Athena GTX’s executives interviewed on "The Street Reports," discuss the relationship between Halberd and Athena and why that relationship is going to advance Halberd’s breakthrough technologies toward government contracts. Listen here: https://thestreetreports.com/halb-ceo-william-hartman-cto-dr-mitchell-felder-and-ceo-of-athena-gtx-mark-darrah-discuss-company-partnership-and-optimistic-2024-on-the-street-reports-podcast-listen-now/ To get the latest on Halberd’s exciting developments, subscribe by submitting ...

Jan 11 2024

Halberd Corporation 2023 Year-End CEO Update and 2024 Goals

By Admin|2024-01-10T20:13:22-05:00January 11th, 2024|Featured, Investor News, News|0 Comments

Jackson Center, PA, January 11, 2024 -- Halberd Corporation (OTC: HALB) made significant advances in its technology development and accomplished major business goals during the second half of 2023. 2023 ACHIEVEMENTS Halberd received from the CDC two sets of antibiotic resistant bacteria and fungi (a total of 60 samples) on which to test its proprietary ...

Jan 9 2024

Halberd Corp. Signs Significant Revenue Sharing Agreement with Athena GTX

By Admin|2024-01-10T05:12:05-05:00January 9th, 2024|Featured, Investor News, Press Releases|0 Comments

Athena will employ its successful history of securing government contracts, spearheading such initiatives Jackson Center, PA January 9, 2024 – Halberd Corporation (OTC-PINK: "HALB”) is thrilled to declare the formalization of a profitable revenue-sharing accord with Athena GTX, Inc., of Johnston, Iowa, (www.athenagtx.com). Athena GTX is a private enterprise specializing in providing medical care solutions ...

Dec 13 2023

Halberd Corporation Signs Multi-Faceted Agreement with CrodenHealth.com

By Admin|2023-12-12T18:17:31-05:00December 13th, 2023|Featured, Investor News, News, Press Releases|0 Comments

Peter Croden, CrodenHealth Chairman, previously executive with Pharmacia & Upjohn (Pfizer), Upjohn Canada, Upjohn Global Animal Health, NephRx, and Parnell Pharmaceuticals Holdings, Ltd. Endeavors to move Halberd forward Jackson Center, PA December 13, 2023 – Halberd Corporation (OTC-PINK: "HALB”) and CrodenHealth.com of Canada agree to produce, market, sell and distribute Halberd’s patented low dose naltrexone ...

Nov 15 2023

Halberd Corporation Plans to Extend Research Partnership with Mississippi State University

By Admin|2023-11-14T18:09:30-05:00November 15th, 2023|Featured, Investor News, News, Press Releases|0 Comments

MSU Research for Halberd to Transcend the TBI Nasal Spray Jackson Center, PA November 15, 2023 – Halberd Corporation (OTC-PINK: "HALB”) is in talks with Mississippi State University (MSU) to extend its original six-month research arrangement by an additional two years, encompassing yet-to-be defined projects. This decision stems from MSU's exceptional performance in the recent ...

Oct 10 2023

Hartman, CEO and Dr. Felder, CTO of Halberd Corp Featured on The Street Reports Podcast

By Admin|2023-10-09T16:58:07-04:00October 10th, 2023|Featured, Investor News, News, Press Releases|0 Comments

Jackson Center, PA, October 10, 2022 – Halberd Corporation (OTC-PINK: "HALB”) Chairman, President and CEO William A. Hartman and Chief Technology Officer, Dr Mitchell S. Felder were recently interviewed on “The Street Reports Podcast” to update the public on several of the company’s important projects: The significant results to-date of Halberd’s proprietary nasal spray testing ...

Oct 4 2023

Halberd’s Traumatic Brain Injury (TBI) Testing Results Replicated at Mississippi State University (MSU)

By Admin|2023-10-03T20:16:16-04:00October 4th, 2023|Investor News, Medical, News, Press Releases|0 Comments

Jackson Center, PA October 4, 2023 – Halberd Corporation’s (OTC-PINK: "HALB”) proprietary nasal spray testing results to mitigate the effects of Traumatic Brain Injury (TBI) at Mississippi State University (MSU) replicated the earlier dramatic results. The latest testing results were very similar to the initial proof of concept testing: 25% reduction in Neuron Specific Enolase ...

Sep 20 2023

Halberd and Athena GTX Collaborate on Advanced Traumatic Brain Injury (TBI) Monitoring and Applications for Government Contracts

By Admin|2023-09-19T19:50:39-04:00September 20th, 2023|Investor News, Medical, News, Press Releases|0 Comments

Jackson Center, PA September 20, 2023 – Halberd Corporation (OTC-PINK: "HALB”) and Athena GTX, Inc, of Johnston, Iowa commenced collaboration on critical development of submissions for government contracts seeking proposals for the detection and treatment of traumatic brain injury (TBI). The initial focus will be on accelerating and fine-tuning Halberd’s proprietary nasal spray for suppressing ...

Previous 123 Next